Skip to main content
. 2020 Sep 11;26(4):516–528. doi: 10.3350/cmh.2020.0016

Table 2.

Risk factors for recurrence within 5 years (overall patients, n=1,451)

Variable Unadjusted
Multivariable
HR (95% CI) P-value HR (95% CI) P-value
Age ≥60 vs. <60 (years) 1.18 (1.02–1.35) 0.025 1.14 (0.97–1.34) 0.108
Male vs. female 1.21 (1.02–1.44) 0.032 1.41 (1.18–1.68) <0.001
Diabetes 1.01 (0.85–1.20) 0.893
HBV vs. others 0.87 (0.74–1.02) 0.089 0.98 (0.81–1.17) 0.795
ALBI grade 2 vs. 1 1.32 (1.16–1.52) <0.001 1.23 (1.06–1.42) 0.007
FIB-4 ≥3.25 vs. <3.25 1.46 (1.28–1.68) <0.001 1.14 (0.97–1.33) 0.116
AFP ≥10 vs. <10 (ng/mL) 1.39 (1.21–1.60) <0.001 1.49 (1.28–1.72) <0.001
Tumor number
 Single Reference Reference
 Two 1.44 (1.12–1.84) 0.004 1.30 (1.01–1.66) 0.041
 Three 2.56 (1.45–4.54) 0.001 2.17 (1.22–3.85) 0.008
Maximal tumor diameter (cm)
 ≤2 Reference
 >2 and ≤5 1.01 (0.88–1.17) 0.877
 >5 1.13 (0.88–1.45) 0.336
Initial treatment modality
 Resection Reference Reference
 RFA* 1.78 (1.55–2.04) <0.001 1.68 (1.45–1.94) <0.001

HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; ALBI, albumin-bilirubin; FIB-4 score, fibrosis-4 score; AFP, alpha-fetoprotein; RFA, radiofrequency ablation.

*

Thirteen patients who received resection and radiofrequency ablation simultaneously were included in this category.